Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Immunol Methods. 2016 Aug;435:60-7. doi: 10.1016/j.jim.2016.05.009. Epub 2016 May 26.

Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.

Author information

1
Department of Pediatrics, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria.
2
Department of Pediatric Nephrology, University Hospital Freiburg, Mathildenstraße 1, 79106 Freiburg, Germany.
3
Department of Pediatric Nephrology, Children's Hospital, University of Bern, Freiburgstraße 18, 3010 Bern, Switzerland.
4
Department of Pediatric Nephrology, Children's Hospital Augsburg, Stenglinstraße 2, 86156 Augsburg, Germany.
5
Department of Nephrology, Philipps-University Marburg, Baldingerstraße, 35033 Marburg, Germany.
6
Department of Internal Medicine IV-Nephrology and Hypertension, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria.
7
Department of Internal Medicine VI-Infectious Diseases, Immunology, Rheumatology, Pneumology, Innsbruck Medical University, 6020 Innsbruck, Austria.
8
Laboratory of Pediatric Nephrology, Department of Development & Regeneration, KU Leuven, 3000 Leuven, Belgium; Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, Netherlands.
9
Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Schöpfstraße 41, 6020 Innsbruck, Austria. Electronic address: reinhard.wuerzner@i-med.ac.at.

KEYWORDS:

Atypical hemolytic uremic syndrome; Complement activation; Eculizumab; Terminal complement complex; Thrombotic microangiopathies

PMID:
27238216
PMCID:
PMC5625999
DOI:
10.1016/j.jim.2016.05.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center